| Literature DB >> 36060668 |
Jun Chen1, Xiaoming Yu1, Guangjin Luo1.
Abstract
Objective: This study is aimed at researching transcranial magnetic stimulation (TMS) effects combined with computer-aided cognitive training (CACT) on cognitive function of children suffering from cerebral palsy and dysgnosia.Entities:
Mesh:
Year: 2022 PMID: 36060668 PMCID: PMC9439888 DOI: 10.1155/2022/5316992
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
Comparison of C-WYCSI scores of young children between two groups before and after treatment (−x ± s, points).
| Group | VIQ score | PIQ score | ||||||
|---|---|---|---|---|---|---|---|---|
| Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | |
| Observation group ( | 42.69 ± 3.65 | 46.09 ± 3.28a | 48.91 ± 3.70a | 54.25 ± 4.46a | 52.84 ± 4.64 | 57.16 ± 4.86a | 60.78 ± 4.18a | 65.38 ± 4.23a |
| Control group ( | 41.71 ± 3.51 | 44.81 ± 3.35a | 47.32 ± 3.33a | 49.48 ± 3.36a | 52.13 ± 4.11 | 57.16 ± 3.48a | 59.52 ± 3.33a | 62.81 ± 4.74a |
|
| 1.083 | 1.542 | 1.783 | 4.778 | 0.646 | 0.005 | 1.327 | 2.269 |
|
| 0.283 | 0.128 | 0.080 | <0.001 | 0.521 | 0.996 | 0.190 | 0.027 |
Note: compared with before treatment, aP < 0.05.
Comparison of C-WISC scores of the older children between two groups before and after treatment (−x ± s, points).
| Group | VIQ score | PIQ score | ||||||
|---|---|---|---|---|---|---|---|---|
| Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | |
| Observation group ( | 51.55 ± 2.66 | 57.55 ± 4.08a | 63.82 ± 3.76a | 74.64 ± 12.04a | 53.82 ± 4.53 | 60.55 ± 4.78a | 63.91 ± 5.96a | 72.73 ± 5.06a |
| Control group ( | 50.92 ± 6.76 | 55.33 ± 5.87 | 59.50 ± 5.32a | 65.08 ± 6.30a | 53.25 ± 2.86 | 56.58 ± 3.34a | 58.42 ± 3.70a | 66.42 ± 5.93a |
|
| 0.298 | 1.040 | 2.228 | 2.414 | 0.363 | 2.320 | 2.681 | 2.732 |
|
| 0.770 | 0.310 | 0.037 | 0.025 | 0.721 | 0.031 | 0.014 | 0.012 |
Note: compared with before treatment, aP < 0.05.
GMFM-88 scores before and after treatment (−x ± s, points).
| Group | A | B | C | D | E | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | |
| Observation group ( | 32.84 ± 3.29 | 36.37 ± 2.84a | 41.55 ± 2.65a | 50.12 ± 4.60a | 16.84 ± 1.09 | 22.47 ± 2.51 | 28.49 ± 2.55 | 35.30 ± 3.20a | 6.53 ± 2.26 | 9.49 ± 2.11 | 13.51 ± 2.32 | 17.21 ± 1.58a | 5.00 ± 1.29 | 8.28 ± 2.25 | 11.44 ± 2.46 | 16.65 ± 3.65a | 2.74 ± 0.95 | 4.63 ± 1.23 | 6.51 ± 1.47 | 9.23 ± 2.38a |
| Control group ( | 32.56 ± 2.93 | 37.21 ± 2.53a | 40.81 ± 2.75a | 44.23 ± 2.83a | 16.51 ± 1.20 | 19.98 ± 2.27 | 25.00 ± 2.80 | 30.74 ± 4.21a | 6.30 ± 1.39 | 6.88 ± 1.33 | 9.37 ± 1.80a | 13.28 ± 4.28a | 5.21 ± 1.30 | 6.95 ± 1.09 | 8.14 ± 1.34 | 10.95 ± 2.48a | 2.65 ± 0.92 | 3.65 ± 0.92 | 4.53 ± 1.16 | 6.60 ± 1.76a |
|
| 0.415 | 1.444 | 1.277 | 7.141 | 1.316 | 4.818 | 6.038 | 5.650 | 0.575 | 6.849 | 9.236 | 5.644 | 0.749 | 3.477 | 7.728 | 8.468 | 0.460 | 4.155 | 6.918 | 5.822 |
|
| 0.679 | 0.152 | 0.205 | <0.001 | 0.192 | <0.001 | <0.001 | <0.001 | 0.567 | <0.001 | <0.001 | <0.001 | 0.456 | 0.001 | <0.001 | <0.001 | 0.647 | <0.001 | <0.001 | <0.001 |
Note: compared with before treatment, aP < 0.05. A: lying motion and turning over; B: sitting motion; C: crawling and kneeling motion; D: standing; E: walking, running, and jumping.
Comparison of cerebral hemodynamic parameters between two groups before and after treatment (−x ± s).
| Group | ACA | MCA | PCA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | Before treatment | Treatment for 3 weeks | Treatment for 6 weeks | Treatment for 12 weeks | |
|
| ||||||||||||
| Observation group ( | 60.20 ± 8.34 | 67.33 ± 5.23 | 74.59 ± 5.40 | 82.90 ± 7.93 | 69.23 ± 6.98 | 76.55 ± 5.28 | 82.38 ± 4.90 | 89.75 ± 7.20 | 52.31 ± 4.39 | 56.87 ± 4.43 | 60.47 ± 4.43 | 66.63 ± 4.79 |
| Control group ( | 58.39 ± 5.81 | 64.60 ± 5.18 | 69.69 ± 5.18 | 76.65 ± 7.55 | 68.14 ± 4.74 | 74.06 ± 4.69 | 79.44 ± 4.42 | 84.29 ± 5.23 | 51.23 ± 4.02 | 55.56 ± 3.11 | 59.54 ± 3.16 | 64.59 ± 3.94 |
|
| 1.168 | 2.437 | 4.295 | 3.741 | 0.852 | 2.319 | 2.924 | 4.026 | 1.189 | 1.584 | 1.117 | 2.156 |
|
| 0.247 | 0.017 | <0.001 | <0.001 | 0.397 | 0.023 | 0.004 | <0.001 | 0.238 | 0.117 | 0.267 | 0.034 |
|
| ||||||||||||
| Observation group ( | 21.43 ± 5.46 | 28.10 ± 3.96 | 32.05 ± 3.88 | 38.32 ± 5.30 | 24.36 ± 5.40 | 30.57 ± 2.55 | 33.57 ± 2.83 | 38.09 ± 3.36 | 15.21 ± 4.70 | 19.61 ± 4.40 | 23.61 ± 4.26 | 30.39 ± 6.83 |
| Control group ( | 22.41 ± 3.41 | 26.69 ± 2.30 | 29.58 ± 3.03 | 33.62 ± 4.42 | 23.67 ± 3.83 | 25.46 ± 3.90 | 30.30 ± 3.77 | 34.63 ± 4.88 | 14.11 ± 2.82 | 17.46 ± 2.75 | 20.80 ± 2.54 | 24.23 ± 3.42 |
|
| 1.003 | 2.017 | 3.300 | 4.475 | 0.688 | 7.191 | 4.553 | 3.824 | 1.315 | 2.717 | 3.719 | 5.287 |
|
| 0.319 | 0.048 | 0.001 | <0.001 | 0.493 | <0.001 | <0.001 | <0.001 | 0.193 | 0.008 | <0.001 | <0.001 |
|
| ||||||||||||
| Observation group ( | 35.36 ± 3.41 | 39.81 ± 2.30 | 43.52 ± 3.72 | 49.27 ± 3.75 | 41.88 ± 4.51 | 47.84 ± 3.03 | 51.76 ± 3.49 | 57.17 ± 4.67 | 26.78 ± 1.79 | 28.76 ± 1.75 | 33.20 ± 5.01 | 36.51 ± 5.78 |
| Control group ( | 36.01 ± 4.42 | 40.27 ± 2.80 | 43.08 ± 2.19 | 46.42 ± 3.32 | 41.02 ± 3.29 | 41.87 ± 3.19 | 46.77 ± 2.76 | 49.79 ± 2.89 | 26.11 ± 1.94 | 28.34 ± 1.19 | 29.99 ± 1.74 | 32.37 ± 2.30 |
|
| 0.770 | 0.837 | 0.673 | 3.721 | 1.008 | 8.914 | 7.353 | 8.811 | 1.672 | 1.282 | 3.971 | 4.364 |
|
| 0.443 | 0.405 | 0.503 | <0.001 | 0.316 | <0.001 | <0.001 | <0.001 | 0.098 | 0.203 | <0.001 | <0.001 |
Note: compared with before treatment, aP < 0.05.